March 2012
Volume 53, Issue 14
ARVO Annual Meeting Abstract  |   March 2012
MT2 Melatonin Receptor-Mediated Inhibition of Nitric Oxide Release and cGMP Production in Human Nonpigmented Ciliary Epithelial Cells
Author Affiliations & Notes
  • Juanita Carnes
    Pharmacol/Toxicol, Morehouse School of Medicine, Atlanta, Georgia
  • Gianluca Tosini
    Pharmacol/Toxicol, Morehouse School of Medicine, Atlanta, Georgia
  • Footnotes
    Commercial Relationships  Juanita Carnes, None; Gianluca Tosini, None
  • Footnotes
    Support  RCMI GRANT RR003034; NIH grants NS43459 and EY 020821
Investigative Ophthalmology & Visual Science March 2012, Vol.53, 3271. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Juanita Carnes, Gianluca Tosini; MT2 Melatonin Receptor-Mediated Inhibition of Nitric Oxide Release and cGMP Production in Human Nonpigmented Ciliary Epithelial Cells. Invest. Ophthalmol. Vis. Sci. 2012;53(14):3271.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: : It is well known that melatonin lowers intraocular pressure (IOP), but the mechanism has not been determined. Previous studies in our laboratory suggest that melatonin inhibits nitric oxide (NO) release and cGMP production in aqueous humor producing human nonpigmented ciliary epithelial (NPCE) cells via activation of MT2 melatonin receptors. The present study was conducted in order to confirm the presence and functional activity of the MT2 subtype in NPCE cells using selective agonists and antagonists of melatonin receptors.

Methods: : NO release protocols were carried out using NPCE cells treated in dye free DMEM containing protease inhibitor cocktail and L-arginine. Cyclic GMP experimental protocols were performed using dye free DMEM containing IBMX. The effects of S27633-1, IIK7 and 5-MCA-NAT, selective MT1, MT2 and putative MT3 receptor agonists, respectively, on SNP-elevated NO and cGMP production were determined in separate experiments. NO and cGMP levels were measured using a colorimetric assay or enzyme immunoassay, respectively. Melatonin receptor agonist selectivity was evaluated using luzindole (nonselective MT1/ MT2 antagonist) or 4-PP-DOT (selective MT2 antagonist).

Results: : IIK7 and 5-MCA-NAT (10-11 - 10-5 M) produced concentration-dependent reduction of NO release and cGMP production, whereas the MT1 receptor agonist, S27633-1, had no effect on NO release. The effects of IIK7 and 5-MCA-NAT on NO release were significantly inhibited in the presence of luzindole and 4-PP-DOT. Further studies are being conducted to determine the effect of the melatonin receptor antagonists on IIK7 and 5-MCA-NAT-induced changes in cGMP production.

Conclusions: : Results from this study demonstrate that, similar to melatonin, 5-MCA-NAT-induced reduction of NO release was completely inhibited by luzindole, thus suggesting that this effect is mediated via activation of MT1 or MT2 receptors and not the MT3 subtype. The effects of IIK7 on NO release are likely mediated by activation of MT2 receptors. In summary, our findings provide evidence of the presence and functional activity of MT2 receptors in our human NPCE cell line. These data suggest that the MT2 receptor plays a role in melatonin receptor agonist-induced reduction of IOP.

Keywords: melatonin • second messengers: pharmacology/physiology • aqueous 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.